This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

MenQuadfi

meningococcal (group A,C,W,Y) conjugate vaccine

MenQuadfi™▼ is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W and Y.

Before you prescribe this vaccine please refer to the SmPC.1

Convenient, fully liquid formulation with no reconstitution required.1MenQuadfi may be used to boost subjects who have previously received a meningococcal vaccine containing the same serogroups.1Thermostable for 72 hours up to 25°C. Reduced likelihood of vaccine wastage due to cold chain errors during shipment and storage.1

.

References
  1. MenQuadfi Summary of Product Characteristics.

MAT-XU-2400154 (v3.0) Date of preparation: April 2025